Loading...
NPI 1053074757 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rainbow Lab Inc is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 3 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rainbow Lab Inc |
| Address | 4001 W Devon Ave Ste 322 |
| City | Chicago |
| State | IL |
| ZIP | 60646 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 19, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $15.1M |
| Medicaid | $9.7M |
The provider operates as a high-volume clinical medical laboratory focused on SARS-CoV-2 diagnostics and related respiratory testing: its top-billing codes are 87637 (multiplex detection of SARS–CoV–2, influenza A/B, RSV), 86328 (SARS–CoV–2 antibody immunoassay), and sequencing/genotyping codes appearing on the Medicaid side (87913). The mix of multiplex molecular testing, serology, specimen-collection, and next-generation sequencing codes indicates a service line centered on diagnostic testing and genomic surveillance rather than routine anatomic pathology or point-of-care services.
Medicare revenue is highly concentrated: the precomputed top-3 Medicare codes account for 100.0% of this provider's total Medicare revenue, led by 87637 at $11.1M (73.3% of Medicare revenue) and 86328 at $3.4M (22.8% of Medicare revenue), with G2023 contributing $591.6K (3.9%). These three codes together represent the entirety of reported Medicare billing, signaling near-exclusive reliance on respiratory/COVID-related molecular and serologic testing for Medicare income.
Medicaid revenue is likewise concentrated in three codes that together represent 100.0% of Medicaid revenue: 87913 drives $4.4M (45.5% of Medicaid revenue), 87637 contributes $4.0M (40.9%), and 86328 adds $1.3M (13.6%). The Medicaid mix shows a heavier relative contribution from genotyping (87913) compared with Medicare, indicating the lab provides substantial sequencing or variant-typing services to Medicaid patients or programs.
On payer mix, this provider reports $15.1M in total Medicare revenue versus $9.7M in total Medicaid revenue, so Medicare is the larger single payer but Medicaid represents a meaningful share of overall business. The presence of sizable revenue on both payers means the lab is not effectively single-payer and must manage contracts and workflows across both Medicare and Medicaid populations.
The provider is a national leader on key Medicare codes: 87637 ranks #3 of 1141 providers nationally (100th percentile; extreme outlier) and 86328 ranks #1 of 119 providers nationally (100th percentile; extreme outlier), while G2023 ranks #7 of 465 (99th percentile; notably above typical national volume). These rank and percentile positions describe the provider as an outsized player for high-volume SARS–CoV–2 multiplex testing and antibody testing on the Medicare side, well above typical national volumes.
Within Illinois Medicaid, competitive standing is similarly strong for core codes: 86328 ranks #1 of 26 providers in-state (100th percentile; extreme outlier) and 87637 ranks #3 of 79 providers in-state (97th percentile; notably above typical state volume), while 87913 ranks #3 of 10 providers in-state (78th percentile; typical, unremarkable volume). This combination indicates dominant serology and high multiplex testing presence in-state, with genotyping/sequencing important but more concentrated among fewer peers.
Claim volumes point to very high throughput laboratory operations: Medicare claim counts include 79.1K claims for 87637 and 78.3K claims for 86328, and Medicaid claim activity includes 29.1K claims for 87913 and 28.5K claims for 87637. The tens of thousands of claims per top code are consistent with centralized, high-capacity processing workflows and substantial specimen-collection throughput.
The provider's NPI was enumerated on 2021-10-19 (~5 years ago), so this is a relatively recent entrant that has rapidly scaled to substantial Medicare and Medicaid volumes. Rapid scaling to the reported $15.1M in Medicare revenue and $9.7M in Medicaid revenue since enumeration suggests fast operational growth focused on COVID-related testing and sequencing services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 79,090 | $140 | $11.1M |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 78,270 | $40 | $3.4M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 25,720 | $20 | $591.6K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 29,050 | $150 | $4.4M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 28,540 | $140 | $4M |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 30,610 | $40 | $1.3M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 50 | $50 | $2.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 50 | $20 | $1.1K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 30 | $10 | $420 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 50 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 3 | 10 | 16,610 | $150 | $2.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 274 | 350 | 400 | $70 | $514.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 3 | 80 | 530 | $130 | $505.1K |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 1 | 30 | 110 | $40 | $95K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 330 | 400 | 550 | $20 | $90.8K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 41 | 60 | 90 | $40 | $35.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 585 | 890 | 90 | $40 | $35K |
Other providers in the same ZIP code as Rainbow Lab Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| S K Diagnostics Inc | IL | Clinical Medical Laboratory | $21.4M | $20.3K |
| Az Labs Limited | IL | Clinical Medical Laboratory | $12.8M | $255.6K |
| Cl Labs Inc. | IL | Clinical Medical Laboratory | $166.5K | $11M |
| Safeena Enterprises Inc | IL | Clinical Medical Laboratory | $8.6M | $0 |
| Chicago Department Of Public Health | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $6.2M |
| Aza Labs Inc | IL | Clinical Medical Laboratory | $1M | $5M |
| County Diagnostic Incorporation | IL | Clinical Medical Laboratory | $5.3M | $92.8K |
| Abdulmassih Abdulmassih | IL | Family Medicine Physician | $374.7K | $3.3M |
| Kyriaki Ades | IL | Dentist | $0 | $3.6M |
| Aim One Incorporated | IL | Durable Medical Equipment & Medical Supplies | $0 | $3.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.